Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer
Stefan Buchholz(University Hospital Regensburg), Gilbert Donders(Institut Scientifique de Santé Publique), Patrick Neven(KU Leuven), Philipp Grob, Olaf Ortmann(University of Regensburg), Anneleen Lintermans(Universitair Ziekenhuis Leuven), M Mögele(University Hospital Regensburg), Gert Bellen(Flemish Community), V. Prasauskas
Cited by 46
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy
|BJOG An International Journal of Obstetrics & Gynaecology|2009|436